Publications by authors named "Seth Seegobin"

Claim this Profile
A
A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19.
Rhiannon Edge, Sam Matthews, Bahar Ahani, Anastasia A Aksyuk, Lindsay Clegg, Seth Seegobin

Nat Commun· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, Abdullahi Ahmad, Tauseefullah Akhund, Seth Seegobin

Lancet Microbe· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials.
Myron J Levin, Andrew Ustianowski, Stephane De Wit, Rohini Beavon, Jesse Thissen, Seth Seegobin

Infect Dis Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and IC values predict SARS-CoV-2 neutralising antibody titres.
Lindsay E Clegg, Oleg Stepanov, Sam Matthews, Tom White, Seth Seegobin

Clin Transl Immunology· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Douglas Arbetter, Seth Seegobin

Infect Dis Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, Paul I Dargan, Ruth Payne

Lancet Microbe· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized Trial.
F D Richard Hobbs, Hugh Montgomery, Francisco Padilla, Jesus Abraham Simón-Campos, Kenneth Kim, Seth Seegobin

Infect Dis Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy Adults.
Pablo Forte-Soto, Muna Albayaty, Dennis Brooks, Rosalinda H Arends, John Tillinghast, Seth Seegobin

J Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic Coronavirus Disease 2019.
Myron J Levin, Andrew Ustianowski, Steven Thomas, Alison Templeton, Yuan Yuan, Seth Seegobin

Clin Infect Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.
Hugh Montgomery, F D Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin

Lancet Respir Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
Myron J Levin, Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Seth Seegobin

N Engl J Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial.
Sophie Glatt, Gregor B E Jemec, Seth Forman, Christopher Sayed, George Schmieder, Seth Seegobin

JAMA Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNASeq_similarity_matrix: visually identify sample mix-ups in RNASeq data using a 'genomic' sequence similarity matrix.
Nicolaas C Kist, Robert A Power, Andrew Skelton, Seth D Seegobin, Moira Verbelen

Bioinformatics· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02.
Christos Tziotzios, Christos Petridis, Nick Dand, Chrysanthi Ainali, Jake R Saklatvala, Seth Seegobin

Nat Commun· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial.
Ruth E Cooper, Emma Williams, Seth Seegobin, Charlotte Tye, Jonna Kuntsi

Eur Neuropsychopharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skin.
Tania Brocks, Oleg Fedorchenko, Nicola Schliermann, Astrid Stein, Ute M Moll, Seth Seegobin

FASEB J· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the standardised assessment of personality--abbreviated scale in a general population sample.
Marcella Lei-Yee Fok, Seth Seegobin, Souci Frissa, Stephani L Hatch, Matthew Hotopf

Personal Ment Health· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.
Hyman Muss, Javier Cortes, Linda T Vahdat, Fatima Cardoso, Chris Twelves, Seth Seegobin

Oncologist· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking.
Ian C Scott, Seth D Seegobin, Sophia Steer, Rachael Tan, Paola Forabosco

PLoS Genet· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial.
Seth D Seegobin, Margaret H Y Ma, Chanaka Dahanayake, Andrew P Cope, David L Scott

Arthritis Res Ther· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.
Javier Cortes, Joyce O'Shaughnessy, David Loesch, Joanne L Blum, Linda T Vahdat, Seth Seegobin

Lancet· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis